RESUMO
The majority of genomic sequencing and microarray results are clinically uninformative, meaning that they do not suggest a need for any behavioral action or medical intervention. Prior studies have shown that recipients of uninformative genomic testing results ("uninformative results" hereafter) may incorrectly interpret them to imply a lowered risk of disease or false reassurance about future health risks. Few studies have examined how patients understand uninformative results when they are returned in a research setting, where there is wide variation in analytical specifications of testing, interpretation and reporting practices, and resources to support the return of results. We conducted cross-sectional interviews (N = 17) to explore how a subset of research participants in one genomics study at the National Institutes of Health reacted to and understood their uninformative test results, which were returned to them via a patient portal without genetic counseling. We found that most participants did not remember the details of the informed consent process, including the distinction between "primary" and "secondary" findings. Participants had questions about what genes were tested for and, in most cases, requested a list of the genes covered. Several participants incorrectly assumed that autosomal recessive carrier results would have been reported to them if detected. Some participants interpreted their uninformative results to mean that they could forgo prenatal testing, and participants had mixed expectations about whether their results might be reinterpreted in the future. These themes suggest that there are specific challenges to returning uninformative results in research settings. Educational supplements to uninformative test reports may be most useful if they contextualize results in relation to other types of clinical genetic or genomic testing that may be made available to research participants in their lifetimes.
RESUMO
Rheumatoid arthritis (RA) is an incurable, systemic autoimmune disease that decreases quality of life and can lead to severe disability. While there are many medications available to treat RA, the first-line of therapy is low-dose methotrexate (MTX), a small molecule disease-modifying anti-rheumatic drug (DMARD). MTX is the recommended therapy due to its affordability and efficacy in reducing symptoms in most RA patients. Unfortunately, there is great person-to-person variability in the physiological response to MTX, with up to 50% of patients showing little response to the medication. Thus, many RA patients initially placed on MTX do not experience an adequate reduction of symptoms, and could have benefited more in both the short and long terms if initially prescribed a different drug that was more effective for them. To combat this problem and better guide treatment decisions, many research groups have attempted to develop predictive tools for MTX response. Currently, there is no reliable, clinical-grade method to predict an individual's response to MTX treatment. In this review, we describe progress made in the area of MTX non-response/resistance in RA patients. We specifically focus on application of the following elements as predictive markers: proteins related to MTX transport and function, intracellular MTX concentration, immune cell frequencies, cytokines, and clinical factors.
Assuntos
Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/metabolismo , Resistência a Medicamentos/fisiologia , Metotrexato/uso terapêutico , Animais , Anticorpos Monoclonais/farmacocinética , Anticorpos Monoclonais/uso terapêutico , Antirreumáticos/farmacocinética , Artrite Reumatoide/imunologia , Resistência a Medicamentos/efeitos dos fármacos , Humanos , Imunidade Celular/efeitos dos fármacos , Imunidade Celular/fisiologia , Mediadores da Inflamação/antagonistas & inibidores , Mediadores da Inflamação/imunologia , Mediadores da Inflamação/metabolismo , Metotrexato/farmacocinética , Valor Preditivo dos Testes , Resultado do TratamentoRESUMO
Rheumatoid arthritis (RA) is a systemic autoimmune disease that causes joint pain, inflammation, and loss of function. Disease pathogenesis involves activation and proliferation of autoreactive pro-inflammatory effector T cells. While the details of RA onset and progression remain controversial, dendritic cell (DC) numbers dramatically increase in the synovial joint tissues of RA patients. Based on their key functions as antigen-presenting cells and inducers of T cell differentiation, DCs may play an important role in the initiation of joint inflammation. Myeloid DC contributions are likely central to the development of RA, as they are more efficient at antigen presentation in comparison with their closely related cousins, plasmacytoid DCs. Synovial fluid in the joints of RA patients is enriched with pro-inflammatory cytokines and chemokines, which may stimulate or result from DC activation. Epidemiological evidence indicates that smoking and periodontal infection are major environmental risk factors for RA development. In this review, factors in the synovial environment that contribute to altered myeloid DC functions in RA and the effects of environmental risk factors on myeloid DCs are described.
Assuntos
Artrite Reumatoide/imunologia , Células Dendríticas/imunologia , Articulações/imunologia , Células Mieloides/imunologia , Animais , Artrite Reumatoide/epidemiologia , Artrite Reumatoide/metabolismo , Artrite Reumatoide/microbiologia , Diferenciação Celular , Proliferação de Células , Microambiente Celular , Células Dendríticas/metabolismo , Células Dendríticas/microbiologia , Interações Hospedeiro-Patógeno , Humanos , Mediadores da Inflamação/imunologia , Mediadores da Inflamação/metabolismo , Articulações/metabolismo , Articulações/microbiologia , Ativação Linfocitária , Células Mieloides/metabolismo , Células Mieloides/microbiologia , Porphyromonas gingivalis/imunologia , Porphyromonas gingivalis/patogenicidade , Fatores de Risco , Transdução de Sinais , Fumar/efeitos adversos , Fumar/imunologia , Membrana Sinovial/imunologia , Membrana Sinovial/metabolismo , Linfócitos T/imunologia , Linfócitos T/metabolismoRESUMO
A 48-year-old man residing in a mental health department inpatient program with a history of schizoaffective disorder presented to the emergency department with a chief complaint of fever and intense abdominal pain for one day. The patient stated he initially fell in the shower and afterwards experienced back pain. He was transferred to an acute care unit within the facility for further evaluation. The facility physician noted that the patient had a mild temperature elevation and abdominal rigidity on exam. At that time, he was given two doses of benztropine intramuscularly, and transferred to our hospital for further evaluation. The patient exhibited fever, diffuse abdominal pain and a nonproductive cough, but denied chills, dysuria, urinary frequency, hematuria, weakness, diarrhea, melena or hematochezia. He did have a one-week history of constipation for which he was given sodium phosphate enemas, magnesium citrate and docusate sodium, eventually resulting in a bowel movement. He also complained of new onset dysphagia. There were no recent changes to his medications, which included clonazepam, divalproex sodium extended release, olanzapine and risperidone. He denied use of tobacco, alcohol or illicit drugs.
Assuntos
Antipsicóticos/toxicidade , Síndrome Maligna Neuroléptica/diagnóstico , Síndrome Maligna Neuroléptica/terapia , Transtornos Psicóticos/tratamento farmacológico , Dor Abdominal/etiologia , Antipsicóticos/classificação , Benzodiazepinas/uso terapêutico , Dantroleno/uso terapêutico , Diagnóstico Diferencial , Agonistas de Dopamina/uso terapêutico , Eletroconvulsoterapia/métodos , Febre/etiologia , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
We describe a general synthetic strategy for developing high-affinity peptide binders against specific epitopes of challenging protein biomarkers. The epitope of interest is synthesized as a polypeptide, with a detection biotin tag and a strategically placed azide (or alkyne) presenting amino acid. This synthetic epitope (SynEp) is incubated with a library of complementary alkyne or azide presenting peptides. Library elements that bind the SynEp in the correct orientation undergo the Huisgen cycloaddition, and are covalently linked to the SynEp. Hit peptides are tested against the full-length protein to identify the best binder. We describe development of epitope-targeted linear or macrocycle peptide ligands against 12 different diagnostic or therapeutic analytes. The general epitope targeting capability for these low molecular weight synthetic ligands enables a range of therapeutic and diagnostic applications, similar to those of monoclonal antibodies.
Assuntos
Desenho de Fármacos , Epitopos/química , Peptídeos Cíclicos/síntese química , Peptídeos Cíclicos/farmacologia , Proteínas/química , Ligantes , Peso Molecular , Peptídeos Cíclicos/química , Proteínas/antagonistas & inibidoresRESUMO
Macrocycle peptides are promising constructs for imaging and inhibiting extracellular, and cell membrane proteins, but their use for targeting intracellular proteins is typically limited by poor cell penetration. We report the development of a cell-penetrant high-affinity peptide ligand targeted to the phosphorylated Ser474 epitope of the (active) Akt2 kinase. This peptide can function as an allosteric inhibitor, an immunoprecipitation reagent, and a live cell immunohistochemical staining reagent. Two cell penetrant stereoisomers were prepared and shown to exhibit similar target binding affinities and hydrophobic character but 2-3-fold different rates of cell penetration. Experimental and computational studies resolved that the ligands' difference in cell penetration could be assigned to their differential interactions with cholesterol in the membrane. These results expand the tool kit for designing new chiral-based cell-penetrant ligands.
RESUMO
Vimentin is an intermediate filament protein traditionally considered to be an intracellular protein with a structural role. However, recent evidence suggests that vimentin can also be found outside the cell in disease conditions such as cancer, traumatic tissue injury, and inflammation. Extracellular vimentin was previously found to stimulate innate immunity by increasing monocyte and macrophage ability to kill bacteria. However, vimentin has also been previously found to decrease neutrophil infiltration into inflamed tissue. How extracellular vimentin affects the initiation of adaptive immune responses is unknown. Initiation of adaptive immunity involves priming of naïve T cells by antigen-presenting cells, the most effective of which are dendritic cells (DCs). In this study, we demonstrate how extracellular vimentin modulates lipopolysaccharide (LPS) - induced activation of human DCs. Using cytometric bead arrays, we show that extracellular vimentin decreases LPS-activated DC secretion of pro-inflammatory cytokines IL-6 and IL-12 while increasing secretion of the anti-inflammatory cytokine IL-10. Using flow cytometry, we show that extracellular vimentin does not significantly affect LPS-induced DC surface expression of MHC I (HLA-ABC) or MHC II (HLA-DR) presentation molecules, costimulatory factors (CD80, CD86), or the DC maturation marker (CD83). Further, LPS-stimulated DCs co-cultured with allogeneic naïve CD4 + T cells (Th0) induced less secretion of the pro-inflammatory Th1 effector cytokine IFN-γ in the presence of vimentin than in the presence of LPS alone. This result suggests that vimentin reduces Th1 differentiation. Taken together, our data suggest that extracellular vimentin may inhibit pro-inflammatory adaptive immune responses, by blocking DC secretion of pro-inflammatory cytokines. Thus, extracellular vimentin may play an important role in cancer or trauma-complications by inducing suppression of the adaptive immune response. In a positive sense, the presence of extracellular vimentin may prevent tissue-damage from contributing to the development of autoimmunity. Consequently, extracellular vimentin may become a novel drug target for treatment of a variety of pro- and anti-inflammatory disease conditions.
Assuntos
Citocinas/imunologia , Células Dendríticas/imunologia , Vimentina/imunologia , Antígenos CD/imunologia , Células Cultivadas , Células Dendríticas/citologia , Antígenos HLA/imunologia , Humanos , Lipopolissacarídeos/farmacologia , Células Th1/citologia , Células Th1/imunologiaRESUMO
INTRODUCTION: Sarcoidosis is a multi-organ system granulomatous disease of unknown origin with an incidence of 1-40/100,000. Though pulmonary manifestations are predominant, ocular sarcoidosis (OS) affects 25-50% of patients with sarcoidosis and can lead to blindness. METHODS: A retrospective, single-center chart review of sarcoidosis cases investigated variables associated with the development of OS. Inclusion criteria were biopsy-proven sarcoidosis, disease duration greater than 1 year, documented smoking status on chart review and documentation of sarcoid-related eye disease. Multivariate analysis identified independent risk factors for OS. RESULTS: Of 269 charts reviewed, 109 patients met inclusion criteria. The OS group had a significantly higher proportion of smokers (71.4%) than without OS (42.0%, p=0.027) with no difference (p=0.61) in median number of pack years. Male sex was significantly higher in the OS group (57.1% versus 26.1%, p=0.009). Median duration of sarcoidosis was higher in the OS group (10 versus 4 years, p=0.031). Multivariate regression identified tobacco exposure (OR=5.25, p=0.007, 95% CI 1.58-17.41), male sex (OR=7.48, p=0.002, 95% CI 2.15-26.01), and age (OR=1.114, p=0.002, 95% CI 1.04-1.19) as concomitant risk factors for the development of OS. CONCLUSION: To date, there are few dedicated investigations of risk factors for OS, especially smoking. This investigation identified male sex, age, and tobacco exposure as independent risk factors for OS. Though disease duration did not withstand regression analysis in this moderately sized group, age at chart review suggests screening for OS should not remit but rather intensify in aging patients with sarcoidosis.
Assuntos
Oftalmopatias/diagnóstico , Oftalmopatias/epidemiologia , Sarcoidose/diagnóstico , Sarcoidose/epidemiologia , Fumar/epidemiologia , Fatores Etários , Idoso , Análise de Variância , Estudos de Coortes , Comorbidade , Feminino , Humanos , Incidência , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Nova Orleans/epidemiologia , Razão de Chances , Prognóstico , Estudos Retrospectivos , Índice de Gravidade de Doença , Fatores Sexuais , Fumar/efeitos adversos , Estatísticas não ParamétricasRESUMO
OBJECTIVE: To determine the efficacy of a single dose of antenatal dexamethasone on the neonatal morbidity and mortality of preterm infants born between 24 weeks to 33 weeks and six days age of gestation at a tertiary government hospital. METHODS: A detailed chart review of both maternal and neonatal records of all neonates born between 24 weeks and 33 weeks and 6 days age of gestation at a tertiary government hospital from January 1, 2011 to December 31, 2013 was done. Patients were grouped based on maternal exposure to antenatal dexamethasone. After which, rate of neonatal deaths and morbidities were recorded. Chi-square test for categorical variables, independent t-test for continuous data and logistic regression were used for analysis. RESULTS: Seven hundred and three maternal-neonatal dyads were included. Of these, 120 (17.1%) were not exposed to any antenatal corticosteroid prior to delivery, 347 (49.4%) were exposed to a single dose of 6-mg dexamethasone, and 236 (33.5%) received a complete course of four doses of 6-mg dexamethasone before preterm delivery. There were better neonatal outcomes from mothers who received completed doses of antenatal corticosteroids than those who received only a single dose, however in comparison to those who have not received any antenatal corticosteroids, the group that received only a single dose had significantly better neonatal outcome. Logistic regression analysis demonstrated that exposure to a single dose of dexamethasone before delivery was associated with reduction in neonatal mortality, and select neonatal morbidities. CONCLUSION: It was observed that there was improved neonatal outcomes in neonates given a single dose dexamethasone compared to those who didn't receive any antenatal corticosteroid. Obstetrician gynecologists should not hesitate in administering antenatal dexamethasone even if completion may not seem feasible.
Assuntos
Humanos , Masculino , Feminino , Adulto , Corticosteroides , Dexametasona , Formas de Dosagem , Mortalidade , Morbidade , Resultado do TratamentoRESUMO
According to the literature, prescription cost and convenience are generally regarded as the most important reasons for buying online. This study examines the availability of selected prescription drugs at some of the online pharmacies in the USA. Specifically, the drugs examined are among the ten most often prescribed by physicians.